Washington D.C. Medical Marijuana Sales Hit Record $10.4 Million in April as Patient Count Tops 116,000
- Washington D.C.’s medical marijuana sales hit a new monthly record in April with $10.4 million, marking a 16.2% increase compared to April 2025 and continuing a steady growth trend from previous months.
- The registered patient base expanded to 116,647 in April, with unique dispensary patients rising to 39,627 and an additional retailer added, totaling 69 active retailers in the district.
- Dispensaries led sales with $6.5 million, followed by manufacturers at $3.1 million and cultivation centers at $822,068; flower remained the top-selling product category.
- In April, in-store sales dominated D.C. resident purchases at $3.75 million, non-resident temporary patients significantly contributed $2.08 million in sales, and the report noted no violations, 13 inspections, and the closure of one unlicensed facility.
Washington D.C.’s medical marijuana market reached a new monthly high in April, with total sales hitting $10,404,293, according to a report (PDF) from the Alcoholic Beverage and Cannabis Administration. That’s up from $9,300,768 in March and $8,521,316 in February, and marks a 16.2% increase from the $8,955,050 sold in April 2025.
The district’s patient base also continued to grow. Total registered D.C. resident patients reached 116,647 in April, up from 109,686 in March and 104,433 in February. The number of unique patients served by a registered dispensary increased to 39,627, compared to 37,759 the prior month. The district also added one retailer in April, bringing the total to 69.
Dispensaries accounted for the largest share of April sales, bringing in $6,519,001, up from $6,255,850 in March. Manufacturers reported $3,063,224 in sales, a sharp increase from $2,470,297 the previous month, while cultivation centers brought in $822,068, up from $574,621.
Among products sold by retailers, flower remained the top category, with $3,356,514 in April sales, up from $3,251,058 in March. Vape cartridges followed at $1,152,235, while infused edibles reached $819,879. Raw pre-rolls also saw strong growth, increasing from $636,519 in March to $705,643 in April.
For D.C. residents specifically, total sales reached $4,006,464 in April, up from $3,842,555 the month before. Total unique D.C. resident patients rose to 24,291, while total unique sales climbed to 66,705. In-store sales accounted for most resident activity, with $3,753,313 in sales, while delivery sales dipped slightly to $253,151.
Non-D.C. resident self-certified temporary patients continued to represent a significant portion of the market. Sales in that category reached $2,079,231 in April, up from $1,938,011 in March, with 13,392 unique patients making purchases. Reciprocity patients, meanwhile, accounted for $433,306 in sales, down from $475,284 the month before.
The April report also shows zero violations observed, 13 scheduled inspections and one unlicensed facility closed. ABCA reported 3,142 pounds of cannabis waste destroyed during the month.